Health insurance company Clover Health (NASDAQ: CLOV) reported revenue ahead of Wall Street’s expectations in Q1 CY2026, with sales up 62% year on year to $749.2 million. The company expects the full year’s revenue to be around $2.87 billion, close to analysts’ estimates. Its GAAP profit of $0.05 per share was $0.02 above analysts’ consensus estimates.

Is now the time to buy CLOV? Find out in our full research report (it’s free for active Edge members).

StockStory’s Take

Clover Health’s first quarter was marked by strong membership expansion and a shift to positive profitability, which management attributed to robust enrollment during the annual election period and improved retention of existing members. CEO Andrew Toy emphasized that the company’s technology-driven care model, especially in its core New Jersey market, has been instrumental in fostering deeper clinical integration and operational efficiency. Management highlighted that these factors, along with enhanced benefit design and increased use of Clover Assistant, were central to the company’s improved operating margin and gross profit performance.

Looking ahead, Clover Health’s full-year guidance is shaped by expectations of continued clinical engagement, ongoing investment in technology, and efficiency gains as the member base matures. Management believes the company’s data-driven approach and AI-enabled care coordination will drive further improvements in retention and economics. Interim CFO Clay Thornton noted that the compounding effect of maturing member cohorts and operational scale through automation are expected to strengthen margin and cash generation, while cautioning that the company remains disciplined in monitoring outpatient utilization and newly implemented policy impacts.

Key Insights from Management’s Remarks

Clover Health’s management pointed to several business model differentiators and operational strategies that contributed to first quarter results and are expected to impact future growth.

• Technology-driven care engagement: Management credited the integration of Clover Assistant—a software platform for physicians—with driving earlier, data-informed interventions and improved clinical outcomes, especially among higher-acuity members.
• Core market leadership: The company’s focus on its New Jersey PPO market has led to a concentration of membership and deeper provider alignment, which management believes creates a virtuous cycle for further growth and economic strength.
• Retention and cohort maturation: High retention rates and cohort maturity were singled out as critical drivers, with management explaining that the economics of each member improve as they remain longer under Clover’s care model, leading to a compounding effect on profitability.
• SG&A efficiency gains: Management emphasized 200 basis points of year-over-year improvement in the SG&A (selling, general, and administrative) expense ratio, citing automation, vendor optimization, and disciplined growth investment as key contributors.
• Home-based care expansion: The company expanded its home care services, enrolling a record number of higher-acuity patients. Management believes this supports cost control and member engagement, as well as improved health outcomes for these members.

Drivers of Future Performance

Clover Health’s forward guidance rests on scaling its technology platform, maturing its membership base, and maintaining operational discipline amid evolving regulatory and industry trends.

• Cohort maturity effect: As newer member cohorts progress under the care model, management expects increasing profitability and cash flow, particularly as the 2025 cohort enters its third year—a stage historically associated with higher margins and lower medical costs in the Medicare Advantage industry.
• AI and data platform investment: Ongoing investments in AI-driven care coordination and automation are projected to enhance both medical cost management and administrative efficiency, serving as structural advantages as the company grows.
• Policy and utilization monitoring: Management is closely watching the impact of recent regulatory changes, such as CMS payment rules and risk adjustment updates, as well as trends in outpatient service utilization and prescription drug benefits, which could introduce variability in margins.

Catalysts in Upcoming Quarters

Looking ahead, the StockStory team will be monitoring (1) the pace at which new member cohorts mature and their impact on profitability, (2) the expansion and effectiveness of Clover Assistant and home-based care services in driving clinical outcomes and retention, and (3) the ability to sustain SG&A efficiency gains as the company scales. The trajectory of outpatient utilization and regulatory developments will remain important variables.

Clover Health currently trades at $2.81, up from $2.67 just before the earnings. At this price, is it a buy or sell? See for yourself in our full research report (it’s free).

Stocks That Trumped Tariffs

ALSO WORTH WATCHING: Top 5 Momentum Stocks. The best time to own a great stock is when the market is finally noticing it. These aren't just high-quality businesses. Something is happening with them right now. Elite fundamentals meeting near-term momentum - both boxes checked at the same time.

Find out which stocks our AI platform is flagging this week. See this week's Strong Momentum stocks - FREE. Get Our Strong Momentum Stocks for Free HERE.

Stocks that have made our list include now familiar names such as Nvidia (+1,326% between June 2020 and June 2025) as well as under-the-radar businesses like the once-micro-cap company Tecnoglass (+1,754% five-year return). Find your next big winner with StockStory today.